Mounjaro on the eMC: what the product information actually tells you

Two documents, two very different audiences

When you search for Mounjaro on the eMC, you will find two documents sitting side by side. The SmPC is the technical reference Eli Lilly submitted to the MHRA for approval; it runs to many pages and uses clinical trial language throughout. The PIL is the shorter leaflet physically included in every pen box. Both are legally binding, both approved by the MHRA, but they serve different readers.

The PIL is designed for you. It explains what to do if you miss a dose, how to inject, and which symptoms need urgent medical attention, all in plain English. The SmPC is designed for the clinician writing your prescription and the pharmacist dispensing it. Its frequency tables, pharmacokinetic data and interaction tables assume a professional who can interpret them. Reading the SmPC as a patient is entirely reasonable (it is public information for a reason) but knowing which document you are holding changes how you should weigh what you read.

If you want the background on tirzepatide as a medicine, a plain-language overview is a better starting point than diving straight into section 5.2 on pharmacokinetics.

Section 4.8 and the side-effect frequency tables: what those percentages mean

This is the section most patients head for, and it is also the one that most benefits from a little clinical translation. Section 4.8 of the Mounjaro SmPC lists adverse reactions by system organ class and frequency band: very common (affecting more than 1 in 10 people), common (1 in 10 to 1 in 100), and so on down to very rare.

The gastrointestinal effects sit in the very common and common bands: nausea, vomiting, diarrhoea, constipation, and reflux all appear there, consistent with what the NHS medicines information for tirzepatide describes. Seeing those words listed in bold, clinical font can feel alarming. In practice, most people experience GI effects most intensely in the days after starting or increasing a dose, and they typically settle within a week or two as the body adjusts.

One thing worth understanding: the SmPC captures everything reported at a statistically relevant frequency across clinical trials involving thousands of participants. A side effect appearing in the table does not mean you will experience it, it means enough people in the trials reported it that it had to be recorded. Your prescriber, who has access to your full medical picture, is far better placed to translate those frequency bands into what they mean for you specifically.

The full tirzepatide eMC reference is worth bookmarking if you plan to read the clinical documentation in depth.

The storage section: the one part patients should always read directly

There is one area of the SmPC where going to the source is genuinely the right move. Section 6.4, covering storage, gives the exact approved conditions for keeping your pen: refrigerated at 2–8°C, away from the freezer element, and the precise room-temperature window you have if refrigeration is temporarily unavailable.

Third-party summaries and patient forums sometimes quote storage rules inaccurately or outdatedly. The eMC version reflects the current approved labelling. If you are travelling, or if your pen has been left out, this section (or the equivalent passage in your PIL) is the definitive answer. Do not rely on general memory or online estimates; the figure in the document is the one your prescriber and pharmacist will refer to.

Questions about specific storage situations are worth raising with the team caring for you. Our frequently asked questions cover several practical storage scenarios, and our prescribers are available seven days a week for aftercare queries.

Using the eMC to have a better conversation with your prescriber

If you are already on Mounjaro or considering it, reading the eMC before your consultation can make that conversation more productive, provided you approach it as preparation rather than self-diagnosis. Note the sections that raised questions, write them down, and bring them to your prescriber rather than drawing conclusions alone.

A few things the eMC does not help with: it will not tell you whether tirzepatide is right for you, what dose you should be on, or how to interpret your individual response to treatment. Those judgements belong with a qualified clinician. The licensed eligibility criteria (broadly, adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related health condition) are set out in section 4.1 of the SmPC, but meeting them on paper is a starting point for assessment, not a guarantee of suitability.

A good overview of how tirzepatide compares to other treatments is on our Mounjaro treatment page, and if you are thinking about what private treatment costs and includes, our Mounjaro prices page sets out what an all-inclusive private prescription actually covers. For anyone starting out, our page on Mounjaro 2mg covers the introductory dose in detail, and those moving up the titration schedule can find guidance on what to expect at the 5mg dose. For anyone ready to take the next step, you can start a free consultation with one of our GPhC-registered prescribers, a real clinician reads your answers the same day, not a piece of software.